These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 26749360)

  • 1. Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach.
    Safonov A; Wang S; Gross CP; Agarwal D; Bianchini G; Pusztai L; Hatzis C
    Breast Cancer Res Treat; 2016 Jan; 155(2):223-34. PubMed ID: 26749360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer.
    Djalalov S; Beca J; Hoch JS; Krahn M; Tsao MS; Cutz JC; Leighl NB
    J Clin Oncol; 2014 Apr; 32(10):1012-9. PubMed ID: 24567430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada.
    Hurry M; Zhou ZY; Zhang J; Zhang C; Fan L; Rebeira M; Xie J
    J Med Econ; 2016 Oct; 19(10):936-44. PubMed ID: 27149298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib.
    Carlson JJ; Canestaro W; Ravelo A; Wong W
    J Med Econ; 2017 Jul; 20(7):671-677. PubMed ID: 28332433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis.
    Raphael J; Helou J; Pritchard KI; Naimark DM
    Eur J Cancer; 2017 Nov; 85():146-154. PubMed ID: 28930692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness and cost-effectiveness of the implantable miniature telescope.
    Brown GC; Brown MM; Lieske HB; Lieske PA; Brown KS; Lane SS
    Ophthalmology; 2011 Sep; 118(9):1834-43. PubMed ID: 21723614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.
    Garrison LP; Lalla D; Brammer M; Babigumira JB; Wang B; Perez EA
    Cancer; 2013 Sep; 119(17):3113-22. PubMed ID: 23775560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
    Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
    Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma.
    Hoyle M; Green C; Thompson-Coon J; Liu Z; Welch K; Moxham T; Stein K
    Value Health; 2010; 13(1):55-60. PubMed ID: 19804431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer.
    Candon D; Healy J; Crown J
    Acta Oncol; 2014 Feb; 53(2):201-8. PubMed ID: 24125103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects.
    Au HJ; Golmohammadi K; Younis T; Verma S; Chia S; Fassbender K; Jacobs P
    Breast Cancer Res Treat; 2009 Apr; 114(3):579-87. PubMed ID: 18443903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
    Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
    Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial.
    Purmonen TT; Pänkäläinen E; Turunen JH; Asseburg C; Martikainen JA
    Acta Oncol; 2011 Apr; 50(3):344-52. PubMed ID: 21299447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Sustainability and new anticancer drugs].
    Perrone F
    Recenti Prog Med; 2015 Jan; 106(1):11-3. PubMed ID: 25621773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer.
    Carlson JJ; Garrison LP; Ramsey SD; Veenstra DL
    Value Health; 2009; 12(1):20-7. PubMed ID: 18647257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis.
    Jansen JP; Gaugris S; Choy EH; Ostor A; Nash JT; Stam W
    Pharmacoeconomics; 2010; 28(4):323-44. PubMed ID: 20222755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review.
    Seo MK; Cairns J
    BMC Cancer; 2021 Sep; 21(1):980. PubMed ID: 34470603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives.
    Lee JA; Bubendorf L; Stahel R; Peters S
    Expert Rev Anticancer Ther; 2013 May; 13(5):625-36. PubMed ID: 23617353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
    Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
    J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland.
    Purmonen T; Martikainen JA; Soini EJ; Kataja V; Vuorinen RL; Kellokumpu-Lehtinen PL
    Clin Ther; 2008 Feb; 30(2):382-92. PubMed ID: 18343276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.